Therapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathies

• 作者: James B.Papizan Shaina N.Porter Akshay Sharma Shondra M.Pruett-Miller
• 来源期刊: 生物医学研究杂志（英文版）
• 年，卷（期）: 2021,（2）
• 所属期刊栏目: REVIEW ARTICLES
• 页码范围: 115-134
• 页数: 20页
• 分类号: Q789
• 语种: 英文

摘要

With advancements in gene editing technologies,our ability to make precise and efficient modifications to the genome is increasing at a remarkable rate,paving the way for scientists and clinicians to uniquely treat a multitude of previously irremediable diseases.CRISPR-Cas9,short for clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9,is a gene editing platform with the ability to alter the nucleotide sequence of the genome in living cells.This technology is increasing the number and pace at which new gene editing treatments for genetic disorders are moving toward the clinic.The β-hemoglobinopathies are a group of monogenic diseases,which despite their high prevalence and chronic debilitating nature,continue to have few therapeutic options available.In this review,we will discuss our existing comprehension of the genetics and current state of treatment for β-hemoglobinopathies,consider potential genome editing therapeutic strategies,and provide an overview of the current state of clinical trials using CRISPR-Cas9 gene editing.